VivoSim Labs, Inc. VIVS
0.14 USD -0.01 (-6.33%)
At closeNov 4, 2026, 7:20 AM EST
0.15 0.00 +1.32%
Pre-market · Nov 4, 7:20 AM ET
0.1383 Day range 0.154
0.1383 52-week range 3.40
- YTD
- -92.07%
- 1 year
- -93.47%
- Market cap
- 2.38M
- EPS (ttm)
- -4.47
- YTD return
- -92.07%
- 1-year return
- -93.47%
- Volume
- 1.51M
- Avg volume
- 2.65M
- Open
- 0.1491
- Previous close
- 0.1533
- Day's range
- 0.1383 – 0.154
- 52-week range
- 0.1383 – 3.40
2Y -5.1400 (-97.35%)
Financials — quick view
VIVS Revenue — quarterly 18.00K
VIVS Net income — quarterly -1.34M
VIVS EPS — quarterly -0.25
News
VivoSim Labs Partners With Chemveda Life Sciences To Test, Screen AI-Derived Drug Compounds In VivoSim's NAMkind 3D Tissue Models 
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test 
VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine 
12 Health Care Stocks Moving In Monday's After-Market Session 
Vivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human Use 
VivoSim Labs Plans To Develop Rat Liver Model To Complement Existing NAMkind Human Liver Platform And Expand Its Liver Toxicology Capabilities 
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Friday's Pre-Market Session - VivoSim Labs Announces First Commercial Sales In China For Its NAMkind Testing Services
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on VIVS — it syncs with the Stock Master app.